Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum

Nasus Pharma (NYSE:NSRX) will present at the Zacks Life Sciences Investor Forum, hosted by VirtualInvestorConferences.com, held virtually on June 24-25, 2026.

Rhea-AI Summary

Nasus Pharma (NYSE:NSRX) will present at the Zacks Life Sciences Investor Forum, hosted by VirtualInvestorConferences.com, held virtually on June 24-25, 2026.

The company’s live presentation is scheduled for June 24, 2026, from 11:00am to 11:30am Eastern Time, with real-time Q&A and a webcast replay available.

Argus Jun 22 session

+1.63% close to close Open Argus

Details

News Market Reaction – NSRX

On Jun 22, the day this news came out, NSRX closed 1.63% above the previous close.

Data tracked by StockTitan Argus for the Jun 22 session.

Market Context

This announcement highlights NSRX’s participation in a life sciences investor forum, adding visibili...

Analysis

This announcement highlights NSRX’s participation in a life sciences investor forum, adding visibility alongside recent insider buying and institutional stakes above 5%. Investors may watch for any new clinical or financing commentary during the presentation.

Key Figures

CEO share purchase: 6,550 Ordinary Shares Purchase price: $3.10 per share CEO total holdings: 163,541 Ordinary Shares +5 more

CEO share purchase

6,550 Ordinary Shares

Open-market buy reported on Form 4 dated June 22, 2026

Purchase price

$3.10 per share

CEO open-market purchase of 6,550 shares

CEO total holdings

163,541 Ordinary Shares

Direct and option-based exposure after June 17, 2026 trade

Balyasny ownership

1,169,910 shares

Schedule 13G beneficial ownership disclosure

Balyasny stake

9.99%

Reported percentage of NSRX common stock class

Shares outstanding

11,710,808 shares

Basis for ownership percentages in Schedule 13G filings

Funicular/Cable Car stake

612,913 Ordinary Shares

Schedule 13G filing by Funicular Funds and affiliates

Funicular ownership

5.2%

Reported beneficial ownership of NSRX common stock

Historical Context

5 past events · Latest: Jun 09

5 events

1. Jun 09

   Preclinical results

   24h Move

   -2.8%

   Positive preclinical PK and safety data for intranasal ondansetron NS003.

2. Jun 01

   KOL event

   24h Move

   -0.6%

   Announcement of virtual KOL event to discuss NS002 Phase 2 data.

3. May 01

   Investor conferences

   24h Move

   +1.9%

   Participation in early May investor conferences with 1x1 meeting availability.

4. Mar 25

   Clinical & earnings

   24h Move

   +10.8%

   Positive NS002 Phase 2 results plus annual financials and pipeline update.

5. Mar 16

   Phase 2 data

   24h Move

   -40.6%

   Positive topline Phase 2 data for NS002 vs EpiPen in anaphylaxis.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

intranasal, pharmacokinetic, schedule 13g, beneficial ownership limitation, +1 more

5 terms

intranasal medical

"a clinical-stage pharmaceutical company focused on the development of innovative intranasal products"

Administration or delivery of a drug or vaccine through the nose, typically via a spray or drops that are absorbed by the nasal tissues. For investors, intranasal products can matter because they often offer easier, needle-free use, faster onset of effect, and potential cost or compliance advantages that can widen a product’s market and affect regulatory review, manufacturing complexity, and commercial prospects — similar to how a convenient app can outsell a clunky desktop program.

pharmacokinetic medical

"reported positive preclinical pharmacokinetic and safety results for NS003"

Pharmacokinetic describes how a drug moves through and leaves the body — how it is absorbed, spread to tissues, broken down and excreted — like tracking a package from pickup to delivery and disposal. For investors, these properties determine effective dose, safety risks, how often a medicine must be taken, and how reliably it works, which in turn influence clinical trial success, regulatory approval chances, production complexity and a drug’s commercial value.

schedule 13g regulatory

"[SCHEDULE 13G] Nasus Pharma Ltd Passive Investment Disclosure (>5%)"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

beneficial ownership limitation regulatory

"Warrants subject to a Beneficial Ownership Limitation that prevents exercise"

A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.

form 4 regulatory

"[Form 4] Nasus Pharma Ltd Insider Trading Activity"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TEL AVIV, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that the Company’s management will present live at the Zacks Life Sciences Investor Forum hosted by VirtualInvestorConferences.com, to be held virtually on June 24-25, 2026.

The event will be conducted as a live, interactive online forum, offering investors and industry professionals within the life sciences community the opportunity to submit questions to management in real time. Nasus invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.com.

A replay of the webcast will be available following the conclusion of the conference.

DATE: June 24^th, 2026  
TIME: 11:00am-11:30am Eastern Time

REGISTER HERE

Management is available for one-on-one meetings on June 24, 2026. Schedule one-on-one meetings here.

It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at www.virtualinvestorconferences.com.

About Nasus Pharma
Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus Pharma’s intranasal powder epinephrine product candidate is being developed as a needle-free alternative to epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle-free, easy-to-use alternatives. Nasus Pharma’s proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. For further information about the Company, please visit www.nasuspharma.com or follow on Twitter (X) or LinkedIn.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. Words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will”, “would,” or the negative of these words, similar expressions or variations of such words are intended to identify forward-looking statements. For example, Nasus Pharma is using forward looking statements in this press release when it discusses: the Company's participation in the Zacks Life Sciences Investor Forum. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Forward-looking statements are based on the Company’s current expectations and are subject to uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s Annual Report on Form 20-F for the year ended December 31, 2025 filed with the SEC on March 25, 2026. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

Company Contact
Nasus Pharma Ltd.
info@nasuspharma.com

Investor Contact
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Nasus Pharma (NSRX) present at the Zacks Life Sciences Investor Forum in 2026?

Nasus Pharma will present on June 24, 2026, from 11:00am to 11:30am Eastern Time. The virtual session is part of the Zacks Life Sciences Investor Forum hosted by VirtualInvestorConferences.com, offering investors a live, interactive format.

How can investors attend Nasus Pharma’s NSRX presentation at the Zacks Life Sciences Investor Forum?

Investors can attend Nasus Pharma’s presentation by registering at VirtualInvestorConferences.com. According to the company, online investors are encouraged to pre-register and run the system check to expedite participation and receive event updates.

Will a replay be available for Nasus Pharma’s (NSRX) Zacks Life Sciences Investor Forum webcast?

Yes, a replay of Nasus Pharma’s webcast will be available after the conference. According to the company, the event is hosted on VirtualInvestorConferences.com, allowing investors to watch the presentation on demand following the live session.

Can investors schedule one-on-one meetings with Nasus Pharma (NSRX) during the June 24, 2026 event?

Yes, management is available for one-on-one meetings on June 24, 2026. According to Nasus Pharma, investors can schedule these meetings through the event platform, offering direct interaction with company leadership.

What type of event is the Zacks Life Sciences Investor Forum featuring Nasus Pharma (NSRX)?

The Zacks Life Sciences Investor Forum is a live, interactive online investor conference. According to the company, it allows investors and industry professionals to attend virtual presentations and submit questions to management in real time.

Who is invited to Nasus Pharma’s NSRX presentation at the Zacks Life Sciences Investor Forum?

Nasus Pharma invites individual and institutional investors, advisors, and analysts interested in life sciences. According to the company, the virtual forum offers live, interactive presentations and Q&A sessions through VirtualInvestorConferences.com.